Considerations for Moderna's move to get an EUA for the COVID-19 vaccine in young kids

Video

Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.

Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.

Related Videos
Juanita Mora, MD
Rupa Wong, MD | Image Credit: Rupa Wong, MD
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago
John Bradley, MD
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support | Image Credit: Dr_Microbe - Image Credit: Dr_Microbe
Related Content
FDA expands label for lipid injectable emulsion to preterm and term neonates | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA expands label for lipid injectable emulsion to preterm and term neonates

May 15th 2024
Article

Approximately 40% of patients who receive PN in the United States as an intravenous source of nourishment are under 18 years of age.

FDA accepts sBLA for dupilumab to treat CRSwNP in patients aged 12 to 17 years | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

FDA accepts sBLA for dupilumab to treat CRSwNP in patients aged 12 to 17 years

May 13th 2024
Article

The federal agency has accepted the sBLA for Priority Review designation, with a target action date of September 15, 2024.

FDA approves ALTUVIIIO updated label for bleed protection in children with hemophilia | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves ALTUVIIIO updated label for bleed protection in children with hemophilia

May 13th 2024
Article

The extended label approval is based on full evidence from the XTEND-Kids study.

DB-OTO improved hearing to normal in child with profound genetic deafness | Image Credit: © Marija - © Marija - stock.adobe.com.

DB-OTO improved hearing to normal in child with profound genetic deafness

May 8th 2024
Article

Data from the ongoing phase 1/2 CHORD trial was presented at the ASGCT annual conference.

Nirsevimab reduced RSV hospitalizations in infants by 82%, new data shows | Image Credit: © Peter Hansen - © Peter Hansen - stock.adobe.com.

Nirsevimab reduced RSV hospitalizations in infants by 82%, new data show

May 2nd 2024
Article

The new data, published in The Lancet, showed that nirsevimab substantially reduced RSV hospitalizations.

BLA resubmitted for lebrikizumab to treat AD patients 12 years and up | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

BLA resubmitted for lebrikizumab to treat AD patients 12 years and up

April 30th 2024
Article

The resubmission was announced in a first quarter, 2024 earnings news release from Lilly, which expects "regulatory action in the second half of 2024."

© 2024 MJH Life Sciences

All rights reserved.